1YBottom 25% of the group
Rank 55 of 63 funds
Return +14.92%
1Y returns of 63 funds in the Health Care group, sorted from highest to lowest. This fund ranks 55No. 1 is SCBGENOME(E) +68.99%
TISCO Biotechnology Healthcare Fund
Shows where this fund stands in its group. Not investment advice · Data as of 4 Nov 2026
TBIOTECH invests through the master fund Polar Capital Funds plc - Biotechnology 98.44%
This fundTBIOTECH
The fund that actually investsPolar Capital Funds plc - BiotechnologyThis fund and the master fund each charge their own fees. See the fees section of this page for the actual fees
Amgen AMGN4.78%
Madrigal Pharmaceuticals MDGL4.40%Data as of 30 Sep 2026 · Top 6 shown, the rest grouped as Other · per Polar Capital fact sheet
Over the past year it was in the bottom 25% of its group; over 5 years it returned +6.09% per year (Top 25% of the group)
No. 1 is SCBGENOME(E) +68.99%
Each bar is one fund in the AIMC Health Care group, sorted from highest to lowest return · Every share class is counted, and only funds with a full track record for the period are included · Calculated from NAV as of 4 Nov 2026
Past performance is not a guarantee of future results
| YTD | 1W | 2W | 1M | 3M | 6M | 1Y | 3Y | 5Y | MAX |
|---|---|---|---|---|---|---|---|---|---|
| +7.68% | +0.65% | +1.76% | +0.80% | −7.24% | +2.44% | +14.92% | +75.39% | +34.42% | +169.42% |
Total return over each period, matching the NAV chart periods · Not annualised
| Year | Jan |
|---|
Largest drawdown in the selected period −33.97% Previous peak 8 Feb 2021 (NAV 20.6259) → Trough 9 May 2022 (NAV 13.6200) · Back to the previous peak on 16 Jul 2024, after 2 years 2 months
Currently −14.36% from the peak NAV of 31.4441 (19 Aug 2026)
Over 5 years, TBIOTECH returned 0.25 per unit of volatility, ranking 2 of 33 funds · The highest is FP HCARE-A (0.44)
กองทุนจะเน้นลงทุนในหน่วยลงทุนของกองทุน Polar Capital Funds plc - Biotechnology ชนิดหน่วยลงทุน I US Dollar (กองทุนหลัก) ซึ่งมีนโยบายลงทุนอย่างน้อย 51% ของมูลค่าทรัพย์สินในตราสารทุนของบริษัทที่ดำเนินธุรกิจเกี่ยวข้องกับเทคโนโลยีชีวภาพ (Biotechnology) การวินิจฉัยโรค (Diagnostics)… Its largest holdings are POLAR CAPITAL FUNDS PLC - BIOTECHNOLOGY FUND 89.98% · ISHARES BIOTECHNOLOGY ETF 8.46% (fact sheet 30 Sep 2026)
Risk level 7 of 8 (High risk). Since 12 Mar 2020, its NAV has fallen as much as −33.97% from its peak.
Actual total expense ratio (TER) 1.36% a year, against a ceiling of 5.00%. Management fee 1.07%. Front-end fee 1.25%. Back-end fee 0.00%. (Fact sheet 30 Sep 2026)
No. Gains or losses accumulate in the NAV, and investors receive their return when they redeem units
Minimum first purchase 1,000 THB, subsequent purchases 1,000 THB. Buy orders accepted until 15:30, sell orders until 15:30, and redemption proceeds are paid T+5
Hedged at the manager's discretion. As of 30 Sep 2026, 90.18% of the value of its foreign investments was hedged
Past performance is not a guarantee of future results · Investing involves risk. Investors should understand the product's features, return conditions and risks before making an investment decision · This fund invests abroad, so investors may lose or gain from exchange rate movements
argenx ARGX4.33%
Insmed INSM4.06%
Alnylam Pharmaceuticals ALNY4.01%
Rhythm Pharmaceuticals RYTM3.99%
Xenon Pharmaceuticals XENE3.85%
Ascendis Pharma ASND3.59%
Arcutis Biotherapeutics ARQT3.51%
Enliven Therapeutics ELVN3.49%Amgen AMGNHospitals, medicines and medical equipment
Hospitals, medicines and medical equipment
argenx ARGXEuropean biotech that makes Vyvgart to treat autoimmune diseases such as myasthenia gravis
Insmed INSMHospitals, medicines and medical equipment
Hospitals, medicines and medical equipment
Hospitals, medicines and medical equipment
Hospitals, medicines and medical equipment
Ascendis Pharma ASNDA Danish drug company developing long-acting hormone drugs, such as growth hormone for children
Hospitals, medicines and medical equipment
Enliven Therapeutics ELVNHospitals, medicines and medical equipment
Based on the master fund's share of this fund's value (98.44% as of 30 Sep 2026) × each stock's weight in the master fund · stocks as of 31 Aug 2026 · fact sheet from Polar Capital · Illustrations are for explanation only, not individual stock recommendations
No. 1 is SCBGENOME(E) +22.37% per year
No. 1 is FP HCARE-A +6.71% per year
| Feb |
|---|
| Mar |
|---|
| Apr |
|---|
| May |
|---|
| Jun |
|---|
| Jul |
|---|
| Aug |
|---|
| Sep |
|---|
| Oct |
|---|
| Nov |
|---|
| Dec |
|---|
| Full year |
|---|
| 2026 | −1.0 | +0.7 | +3.6 | +1.8 | +0.3 | +12.2 | −1.9 | +2.9 | −8.9 | +0.0 | −1.1 | · | +7.7* |
| 2025 | +2.6 | −3.0 | −8.0 | +2.6 | −5.2 | +5.2 | +7.5 | +8.5 | +6.0 | +10.6 | +9.0 | −4.2 | +33.7 |
| 2024 | −0.2 | +5.4 | −0.4 | −7.5 | +0.6 | +5.1 | +5.8 | −0.1 | −5.8 | +1.4 | +5.2 | −7.1 | +1.0 |
| 2023 | +4.2 | −3.6 | −2.0 | +4.0 | −4.0 | +0.5 | −1.1 | −1.3 | −4.5 | −5.9 | +9.4 | +16.7 | +10.6 |
| 2022 | −12.6 | −2.0 | +6.5 | −10.1 | −1.0 | +5.4 | +5.3 | −1.9 | −5.0 | +6.4 | +2.1 | −1.9 | −10.6 |